Home  |   Archive  |   Online Submission  |   News & Events  |   Subscribe  |   APFA  |   Society  |   Contact Us  |   中文版
Search   
 
Journal

-Ahead of print
-Authors' Accepted
    Manuscripts
new!
-Current Issue
-Archive
-Acknowledgments
-Special Issues
-Browse by Category

Manuscript Submission

-Online Submission
-Online Review
-Instruction for Authors
-Instruction for Reviewers
-English Corner new!

About AJA

-About AJA
-Editorial Board
-Contact Us
-News

Resources & Services

-Advertisement
-Subscription
-Email alert
-Proceedings
-Reprints

Download area

-Copyright licence
-EndNote style file
-Manuscript word template
-Guidance for AJA figures
    preparation (in English)

-Guidance for AJA figures
    preparation (in Chinese)

-Proof-reading for the
    authors

-AJA Club (in English)
-AJA Club (in Chinese)

 
Abstract

Volume 16, Issue 5 (September 2014) 16, 735–739; doi: 10.4103/1008-682X.131064

Chronic bacterial prostatitis and irritable bowel syndrome: effectiveness of treatment with rifaximin followed by the probiotic VSL#3

Enzo Vicari1,*, Sandro La Vignera1,*, Roberto Castiglione1, Rosita A Condorelli1, Lucia O Vicari2, Aldo E Calogero1

1Section of Endocrinology, Andrology and Internal Medicine, Department of Medical and Pediatric Sciences, 2Master in Experimental and Clinical Medicine and Cellular Physiopathology, University of Catania, Catania, Italy.
*These authors contributed equally to this work.

Correspondence: Dr. S La Vignera (sandrolavignera@unict.it)

Received: 12 October 2013; Revised: 12 January 2014; Accepted: 20 February 2014

Abstract

This study was undertaken to evaluate the influence of treatment with rifaximin followed by the probiotic VSL#3 versus no treatment on the progression of chronic prostatitis toward chronic microbial prostate‑vesiculitis (PV) or prostate‑vesiculo‑epididymitis (PVE). A total of 106 selected infertile male patients with bacteriologically cured chronic bacterial prostatitis (CBP) and irritable bowel syndrome (IBS) were randomly prescribed rifaximin (200 mg, 2 tablets bid, for 7 days monthly for 12 months) and probiotic containing multiple strains VSL#3 (450 × 109 CFU per day) or no treatment. Ninety‑five of them (89.6%) complied with the therapeutic plan and were included in this study. Group A = “6Tx/6‑”: treatment for the initial 6 and no treatment for the following 6 months (n = 26); Group B = “12Tx”: 12 months of treatment ( 22); Group C = “6‑/6Tx”: no treatment for the initial 6 months and treatment in the last 6 months ( 23); Group D = “12‑”: no treatment ( 24). The patients of Groups A = “6Tx/6‑” and B = “12Tx” had the highest frequency of chronic prostatitis (88.5% and 86.4%, respectively). In contrast, group “12‑”: patients had the lowest frequency of prostatitis (33.4%). The progression of prostatitis into PV in groups “6Tx/6‑” (15.5%) and “6‑/6Tx” (13.6%) was lower than that found in the patients of group “12‑” (45.8%). Finally, no patient of groups “6Tx/6‑” and “6‑/6Tx” had PVE, whereas it was diagnosed in 20.8% of group “12‑” patients. Long‑term treatment with rifaximin and the probiotic VSL#3 is effective in lowering the progression of prostatitis into more complicated forms of male accessory gland infections in infertile patients with bacteriologically cured CBP plus IBS.

Keywords: chronic bacterial prostatitis; irritable bowel syndrome; probiotic VSL#3; prostate‑vesiculitis; prostate‑vesiculo‑epididymitis; rifaximin

Full Text | PDF | 中文摘要 |

 
Browse:  2370
 
Asian Journal of Andrology CN 31-1795/R ISSN 1008-682X  Copyright © 2023  Shanghai Materia Medica, Chinese Academy of Sciences.  All rights reserved.